PC
MCID: PRS040
MIFTS: 97

Prostate Cancer (PC)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer

MalaCards integrated aliases for Prostate Cancer:

Name: Prostate Cancer 56 12 25 73 36 13 54 6 42 3 15 37 62
Prostate Carcinoma 12 25 54 15 17 71
Prostate Cancer, Familial 56 12 74 52 71
Prostate Neoplasm 12 25 29 6
Familial Prostate Cancer 52 58 29
Prostatic Neoplasms 54 43 71
Prostatic Cancer 12 25 15
Prostate Cancer, Susceptibility to 56 6
Malignant Neoplasm of Prostate 71 32
Malignant Tumor of Prostate 29 6
Hereditary Prostate Cancer 12 52
Prostate Cancer, Somatic 56 6
Prostatic Neoplasm 12 25
Prostate Cancer, Familial, Susceptibility to 56
Malignant Neoplasm of the Prostate 25
Malignant Tumor of the Prostate 12
Ngp - New Growth of Prostate 12
Prostate Cancer, Hereditary 52
Cancer of the Prostate 25
Tumor of the Prostate 12
Carcinoma of Prostate 12
Prostatic Carcinoma 25
Cancer of Prostate 12
Cancer, Prostate 39
Prca 73
Pc 73

Characteristics:

Orphanet epidemiological data:

58
familial prostate cancer
Prevalence: 1-9/100000 (United States); Age of onset: Adult;

OMIM:

56
Inheritance:
somatic mutation
autosomal dominant


HPO:

31
prostate cancer:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:

Orphanet: 58  
Rare urogenital diseases


External Ids:

Disease Ontology 12 DOID:10283 DOID:10286
OMIM 56 176807
KEGG 36 H00024
ICD9CM 34 185
MeSH 43 D011471
SNOMED-CT 67 93974005
ICD10 32 C61
MESH via Orphanet 44 C537243
ICD10 via Orphanet 33 C61
UMLS via Orphanet 72 C2931456
Orphanet 58 ORPHA1331
MedGen 41 C0376358
SNOMED-CT via HPO 68 124975008 263681008 399068003
UMLS 71 C0033578 C0376358 C0600139 more

Summaries for Prostate Cancer

Genetics Home Reference : 25 Prostate cancer is a common disease that affects men, usually in middle age or later. In this disorder, certain cells in the prostate become abnormal and multiply without control or order to form a tumor. The prostate is a gland that surrounds the male urethra and helps produce semen, the fluid that carries sperm. Early prostate cancer usually does not cause pain, and most affected men exhibit no noticeable symptoms. Men are often diagnosed as the result of health screenings, such as a blood test for a substance called prostate specific antigen (PSA) or a medical procedure called a digital rectal exam. As the tumor grows larger, signs and symptoms can include difficulty starting or stopping the flow of urine, a feeling of not being able to empty the bladder completely, blood in the urine or semen, or pain with ejaculation. However, these changes can also occur with many other genitourinary conditions. Having one or more of these symptoms does not necessarily mean that a man has prostate cancer. The severity and outcome of prostate cancer varies widely. Early-stage prostate cancer can usually be treated successfully, and some older men have prostate tumors that grow so slowly that they may never cause health problems during their lifetime, even without treatment. In other men, however, the cancer is much more aggressive; in these cases, prostate cancer can be life-threatening. Some cancerous tumors can invade surrounding tissue and spread to other parts of the body. Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers. The signs and symptoms of metastatic cancer depend on where the disease has spread. If prostate cancer spreads, cancerous cells most often appear in the lymph nodes, bones, lungs, liver, or brain. Bone metastases of prostate cancer most often cause pain in the lower back, pelvis, or hips. A small percentage of all prostate cancers cluster in families. These hereditary cancers are associated with inherited gene mutations. Hereditary prostate cancers tend to develop earlier in life than non-inherited (sporadic) cases.

MalaCards based summary : Prostate Cancer, also known as prostate carcinoma, is related to prostate disease and breast cancer, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Prostate Cancer is CHEK2 (Checkpoint Kinase 2), and among its related pathways/superpathways are Prostate cancer and Transcriptional misregulation in cancer. The drugs Levofloxacin and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and breast, and related phenotypes are prostate cancer and cellular

Disease Ontology : 12 A male reproductive organ cancer that is located in the prostate.

NIH Rare Diseases : 52 Familial prostate cancer is a cluster of prostate cancer within a family. Most cases of prostate cancer occur sporadically in people with no family history of the condition. However, approximately 5% to 10% of prostate cancer cases are believed to be primarily caused by a genetic predisposition to the condition. In many families, the underlying genetic cause is unknown; however, some of these cases are caused by changes (mutations ) in the BRCA1 , BRCA2 , HOXB13 , or several other genes . Other cases are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle. High-risk cancer screening at an earlier age is typically recommended in men who have an increased risk for prostate cancer based on personal and/or family histories.

MedlinePlus : 42 The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is common among older men. It is rare in men younger than 40. Risk factors for developing prostate cancer include being over 65 years of age, family history, and being African-American. Symptoms of prostate cancer may include Problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling Low back pain Pain with ejaculation To diagnose prostate cancer, you doctor may do a digital rectal exam to feel the prostate for lumps or anything unusual. You may also get a blood test for prostate-specific antigen (PSA). These tests are also used in prostate cancer screening, which looks for cancer before you have symptoms. If your results are abnormal, you may need more tests, such as an ultrasound, MRI, or biopsy. Treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. You may have a combination of treatments. NIH: National Cancer Institute

CDC : 3 Cancer is a disease in which cells in the body grow out of control. When cancer starts in the prostate, it is called prostate cancer. Not including skin cancer, prostate cancer is the most common cancer in American men.

KEGG : 36 Prostate cancer constitutes a major health problem in Western countries. It is the most frequently diagnosed cancer among men and the second leading cause of male cancer deaths. The identification of key molecular alterations in prostate-cancer cells implicates carcinogen defenses (GSTP1), growth-factor-signaling pathways (NKX3.1, PTEN, and p27), and androgens (AR) as critical determinants of the phenotype of prostate-cancer cells. Glutathione S-transferases (GSTP1) are detoxifying enzymes. Cells of prostatic intraepithelial neoplasia, devoid of GSTP1, undergo genomic damage mediated by carcinogens. NKX3.1, PTEN, and p27 regulate the growth and survival of prostate cells in the normal prostate. Inadequate levels of PTEN and NKX3.1 lead to a reduction in p27 levels and to increased proliferation and decreased apoptosis. Androgen receptor (AR) is a transcription factor that is normally activated by its androgen ligand. During androgen withdrawal therapy, the AR signal transduction pathway also could be activated by amplification of the AR gene, by AR gene mutations, or by altered activity of AR coactivators. Through these mechanisms, tumor cells lead to the emergence of androgen-independent prostate cancer.

Novus Biologicals : 55 Prostate cancer is the most common non-skin cancer and second most deadly cancer for men in the United States. Prostate cancer occurs when cells within the prostate grow uncontrollably and create small tumors. If untreated, cells from these tumors can spread via metastasis. Metastasis transports prostate cancer cells through the lymphatic system and bloodstream to other parts of the body where they can grow into secondary tumors. PSA, a protein produced by the prostate, is released into the bloodstream in small amounts under normal conditions. However, PSA is released in increasing amounts when the prostate is malfunctioning, as is the case with prostate cancer.

UniProtKB/Swiss-Prot : 73 Prostate cancer: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.

PubMed Health : 62 About prostate cancer: Prostate cancer develops when cells in the prostate start multiplying uncontrollably. This can happen if the genetic information (DNA) in the cells has changed (mutated). The body’s immune system usually keeps these cells in check. Cancer develops if too many mutated cells multiply and a tumor grows. The diagnosis “prostate cancer” usually comes as a shock to men and those close to them. The good news is that prostate cancer is one of the types of cancer with the best chances of recovery. This is because it often grows very slowly so it is generally possible to treat it effectively.

Wikipedia : 74 Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system.... more...

More information from OMIM: 176807

Related Diseases for Prostate Cancer

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 1 Prostate Cancer, Hereditary, 8
Prostate Cancer, Hereditary, 3 Prostate Cancer, Hereditary, 4
Prostate Cancer, Hereditary, 5 Prostate Cancer, Hereditary, 6
Prostate Cancer, Hereditary, 7 Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 10 Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 13 Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 14 Prostate Cancer, Hereditary, 15
Prostate Cancer, Hereditary, 2 Prostate Carcinoma in Situ

Diseases related to Prostate Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1426)
# Related Disease Score Top Affiliating Genes
1 prostate disease 34.8 MIR23B MIR222 MIR221 MIR21 MIR17 MIR146A
2 breast cancer 34.6 TP53 PTEN PIK3CA MIR222 MIR221 MIR21
3 bladder cancer 34.4 TP53 PTEN PIK3CA MIR23B MIR222 MIR221
4 suppression of tumorigenicity 12 34.4 TP53 PTEN PIK3CA MIR145 KLF6 CDH1
5 hereditary breast ovarian cancer syndrome 34.3 TP53 PTEN CHEK2 BRCA2
6 lung cancer 34.1 TP53 PTEN POLK PIK3CA MIR222 MIR221
7 ovarian cancer 34.1 TP53 PTEN PIK3CA MIR222 MIR221 MIR21
8 hepatocellular carcinoma 33.8 TP53 PTEN PIK3CA MIR23B MIR222 MIR221
9 adenocarcinoma 33.7 TP53 PTEN PIK3CA CDH1 BRCA2
10 gastric cancer 33.6 ZFHX3 TP53 PTEN PIK3CA MIR222 MIR221
11 pancreatic cancer 33.4 TP53 PTEN PIK3CA MIR23B MIR222 MIR221
12 renal cell carcinoma, nonpapillary 33.4 TP53 PTEN PIK3CA MIR23B MIR221 MIR21
13 colorectal adenoma 33.4 TP53 MIR21 MIR17 CDH1
14 esophageal cancer 33.3 TP53 PTEN PIK3CA MIR21 MIR205 MIR146A
15 leukemia, acute myeloid 33.3 TP53 PTEN MIR23B MIR222 MIR221 MIR21
16 melanoma 33.3 TP53 PTEN PIK3CA MIR23B MIR222 MIR221
17 lung cancer susceptibility 3 33.1 TP53 PTEN PIK3CA MIR23B MIR21 MIR205
18 glioblastoma multiforme 33.1 TP53 PTEN PIK3CA MIR221 MIR21 CHEK2
19 cervical cancer 33.0 TP53 PTEN PIK3CA MIR23B MIR21 MIR205
20 endometrial cancer 32.9 TP53 PTEN PIK3CA MIR145 CDH1 BRCA2
21 neuroblastoma 32.9 TP53 PTEN PIK3CA MIR23B MIR221 MIR21
22 lynch syndrome 32.8 TP53 PTEN PIK3CA MIR17 CHEK2 BRCA2
23 kidney cancer 32.8 TP53 PTEN PIK3CA MIR21 MIR17
24 leukemia, chronic lymphocytic 32.7 TP53 PTEN MIR23B MIR221 MIR21 MIR17
25 myeloma, multiple 32.7 TP53 PTEN MIR21 MIR17 CDH1
26 body mass index quantitative trait locus 11 32.6 TP53 MIR222 MIR21 MIR17 BRCA2 AR
27 in situ carcinoma 32.6 TP53 PTEN MIR17 CDH1 BRCA2
28 glioma 32.6 TP53 PTEN PIK3CA MIR222 MIR221 MIR21
29 thyroid carcinoma 32.6 TP53 PTEN PIK3CA CDH1
30 pancreatic ductal adenocarcinoma 32.5 TP53 PTEN MIR222 MIR221 MIR21 MIR205
31 squamous cell carcinoma, head and neck 32.5 TP53 PTEN PIK3CA MIR221 MIR21 MIR205
32 bladder urothelial carcinoma 32.5 TP53 PTEN PIK3CA CDH1 AR
33 squamous cell carcinoma 32.5 TP53 PTEN PIK3CA MIR205 CHEK2 CDH1
34 small cell carcinoma 32.4 TP53 PTEN AR
35 vascular disease 32.4 TP53 MIR221 MIR21 MIR146A MIR145
36 lymphoma, non-hodgkin, familial 32.4 TP53 PTEN PIK3CA MIR23B MIR222 MIR21
37 wilms tumor 1 32.4 TP53 CHEK2 CDH1 BRCA2 AR
38 brain cancer 32.4 TP53 PTEN PIK3CA MXI1 MIR17 BRCA2
39 pancreatic adenocarcinoma 32.4 TP53 PTEN PIK3CA MIR221 MIR21 MIR145
40 nasopharyngeal carcinoma 32.4 TP53 PTEN PIK3CA MIR21 MIR205 MIR17
41 basal cell carcinoma 32.3 TP53 PTEN CHEK2 CDH1 AR
42 papilloma 32.3 TP53 PTEN CHEK2 CDH1
43 ductal carcinoma in situ 32.3 TP53 PTEN PIK3CA MIR17 CDH1 BRCA2
44 diffuse large b-cell lymphoma 32.3 TP53 PTEN MIR222 MIR221 MIR21 MIR17
45 bilateral breast cancer 32.2 PTEN PIK3CA CHEK2 CDH1 BRCA2
46 colon adenocarcinoma 32.2 TP53 PTEN PIK3CA MIR21 CDH1
47 glioma susceptibility 1 32.2 TP53 PTEN PIK3CA MIR23B MIR222 MIR221
48 lung squamous cell carcinoma 32.2 TP53 PTEN PIK3CA MIR145 CDH1 BRCA2
49 sporadic breast cancer 32.2 TP53 PTEN MIR146A CHEK2 BRCA2
50 carcinosarcoma 32.1 TP53 PTEN PIK3CA CDH1

Comorbidity relations with Prostate Cancer via Phenotypic Disease Network (PDN): (show all 34)


Acute Kidney Failure Anthracosis
Asbestosis Azoospermia
Balanoposthitis Bladder Cancer
Bladder Neck Obstruction Cystitis Cystica
Deficiency Anemia Disseminated Intravascular Coagulation
Epididymo-Orchitis Gout
Hydronephrosis Kidney Disease
Lipoma of Spermatic Cord Lymphadenitis
Nephrolithiasis, X-Linked Recessive, with Renal Failure Oligospermia
Paralytic Ileus Paraplegia
Prostate Calculus Prostate Carcinoma in Situ
Prostate Disease Prostatic Hypertrophy
Prostatitis Radiation Cystitis
Spermatocele Spinal Cord Disease
Ureterolithiasis Urethral Benign Neoplasm
Urethral Calculus Urethral Stricture
Urethritis Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostate Cancer:



Diseases related to Prostate Cancer

Symptoms & Phenotypes for Prostate Cancer

Human phenotypes related to Prostate Cancer:

31
# Description HPO Frequency HPO Source Accession
1 prostate cancer 31 HP:0012125

Symptoms via clinical synopsis from OMIM:

56
Neoplasia:
early onset prostate cancer

Clinical features from OMIM:

176807

UMLS symptoms related to Prostate Cancer:


tremor, angina pectoris, equilibration disorder

MGI Mouse Phenotypes related to Prostate Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 AR BRCA2 CDH1 CHEK2 KLF6 MAD1L1
2 endocrine/exocrine gland MP:0005379 9.9 AR BRCA2 CDH1 CHEK2 KLF6 MAD1L1
3 neoplasm MP:0002006 9.65 AR BRCA2 CDH1 CHEK2 MAD1L1 MXI1
4 reproductive system MP:0005389 9.36 AR BRCA2 CDH1 CHEK2 KLF6 MAD1L1

Drugs & Therapeutics for Prostate Cancer

PubMed Health treatment related to Prostate Cancer: 62

The possible treatment options for prostate cancer will depend on various factors. These include: how much the cells have changed (how aggressive the tumor is) how much the tumor has grown or spread (the stage of prostate cancer ) the man’s PSA levels individual factors such as the man’s age, how healthy he is otherwise, and how important the pros and cons are to him. Men who have high-risk prostate cancer will usually have their prostate surgically removed or treatment with radiotherapy. Radiotherapy can be done in two ways: from outside of the body (external radiotherapy) or from inside the body (internal radiotherapy , or brachytherapy ). The most common side effects of radiotherapy or removing the prostate gland are accidental leakage of urine (urinary incontinence ) and erection problems (impotence). External radiotherapy is especially likely to cause diarrhea , and in some cases inflammations in the bowel which may result in blood in the stool and cramps . If the tumor is small, only inside the prostate , and not aggressive (low-risk prostate cancer ), the following treatments are also possible: Active surveillance : Here the prostate cancer is simply monitored, and not treated, at first. This strategy is based on the fact that low-risk prostate cancer usually grows very slowly or doesn't grow at all. It is often found that the cancer has still not advanced even years after it was diagnosed. Instead of having treatment , the prostate is checked regularly. Treatment attempting to get rid of the cancer (curative treatment) is only started if the tumor starts growing. The advantage of this approach is that the side effects of surgery or radiotherapy can be avoided as long as the cancer does not grow. One possible disadvantage: If the cancer does progress, that is sometimes discovered too late. It may have already spread to other parts of the body by then (metastasis ). Knowing that you have cancer in your body can be distressing too. Watchful waiting : This strategy also starts by only monitoring the prostate cancer at first. But if the tumor starts growing, only the symptoms are treated, not the tumor itself (this is known as “palliative care ). This approach is mainly considered in older men, who may also have other medical problems. The risks and stress of surgery or radiotherapy could outweigh the possible benefits of this treatment . There is no “right” or “wrong” treatment decision for men who have low-risk prostate cancer . The strategy that one man chooses will mainly depend on his personal preferences and values. Some will feel it is more important to avoid side effects like impotence or incontinence as much as possible. Others will want to be very sure that the cancer has been removed, so they are willing to accept the risks associated with treatment. For more advanced stages of prostate cancer , there are several kinds of hormonal treatments and chemotherapies that aim to slow the growth.

Drugs for Prostate Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 905)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
2
Ofloxacin Approved Phase 4 82419-36-1 4583
3
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
4
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
5
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
6
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Nitric Oxide Approved Phase 4 10102-43-9 145068
9
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
10
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
11
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
12
Desflurane Approved Phase 4 57041-67-5 42113
13
Ondansetron Approved Phase 4 99614-02-5 4595
14
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
15
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
16
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
17
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
18
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
19
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
20
Polyestradiol phosphate Approved Phase 4 28014-46-2
21
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
22
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
23
Pasireotide Approved Phase 4 396091-73-9 9941444
24
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
25
Cabergoline Approved Phase 4 81409-90-7 54746
26
Sulfamethoxazole Approved Phase 4 723-46-6 5329
27
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
28
Fosfomycin Approved Phase 4 23155-02-4 446987
29
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
30
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
31
Zoledronic Acid Approved Phase 4 118072-93-8 68740
32
Denosumab Approved Phase 4 615258-40-7
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
34
Remifentanil Approved Phase 4 132875-61-7 60815
35
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
36
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
37
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
38
tannic acid Approved Phase 4 1401-55-4
39
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
40
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
41
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
42
Pamidronate Approved Phase 4 40391-99-9 4674
43
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
44
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
45
4-Aminopyridine Approved Phase 4 504-24-5 1727
46
Methyltestosterone Approved Phase 4 58-18-4 6010
47
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
48
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
49
Testosterone enanthate Approved Phase 4 315-37-7 9416
50
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271

Interventional clinical trials:

(show top 50) (show all 4899)
# Name Status NCT ID Phase Drugs
1 Comparison of Health Related Quality of Life and Other Clinical Parameters Between ThinSeed™ and OncoSeed™ for Permanent Low Dose Rate Implantation in Localized Prostate Cancer Unknown status NCT01379742 Phase 4
2 Intermittent Vs Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
3 Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer Unknown status NCT01352598 Phase 4
4 METformin And Longevity (METAL): A Window of Opportunity Study Investigating Biological Effects of Metformin in Localised Prostate Cancer Unknown status NCT02511665 Phase 4 Metformin;Placebo
5 Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer Unknown status NCT02757365 Phase 4 aspirin;Levofloxacin
6 MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer? Unknown status NCT00185029 Phase 4
7 A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy Unknown status NCT03142542 Phase 4 ZYDENA TAB.75mg(Udenafil 75mg);Placebo Oral Tablet
8 Use of Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis, Prediction of Clinical Outcome and Monitoring of Treatment Response to Neoadjuvant Chemotherapy Unknown status NCT01956409 Phase 4 18F-FCH;Magnevist
9 To Investigate Post-procedure Hemorrhage and Cardiovascular Events in Taiwanese Patients Who Continue or Discontinue Low-Dose Aspirin Before Transrectal Prostate Biopsy: a Prospective Randomized Trial Unknown status NCT02744937 Phase 4 Aspirin
10 Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis Unknown status NCT02796794 Phase 4
11 A Randomised Pilot Study to Evaluate the Effect(s) of Casodex 150 mg and Zoladex 3.6 mg on Pathological and Genomic Tumour Markers in Subjects Undergoing Radical Prostatectomy for Localised Prostate Carcinoma Completed NCT00293696 Phase 4 bicalutamide (Casodex), goserelin (Zoladex)
12 A Multicenter, Open-label Study to Determine the Effect of iv. Zoledronic Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer Completed NCT00434317 Phase 4 Zoledronic acid
13 A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer Completed NCT00220194 Phase 4 leuprolide acetate
14 An Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa
15 Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test Completed NCT01296672 Phase 4 Finasteride;Placebo
16 A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
17 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4 Zoledronic acid
18 A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT) Completed NCT03035032 Phase 4 Leuprolide
19 Phase IV Study of Safety and Efficacy of Docetaxel in Combination With Prednisone in Advanced Hormone Refractory Prostate Cancer Treatment Completed NCT00280098 Phase 4 docetaxel
20 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4 Zoledronic acid
21 Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer Completed NCT01511874 Phase 4 ELIGARD 22.5mg
22 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
23 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
24 A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure Completed NCT01977651 Phase 4 Enzalutamide
25 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4 Zoledronic acid
26 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy. Completed NCT00237146 Phase 4 Zoledronic acid
27 A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate Completed NCT02116582 Phase 4 Enzalutamide
28 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4 Zoledronic acid
29 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4 Zoledronic acid
30 A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
31 A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management Completed NCT00363311 Phase 4 Dutasteride;Matching placebo
32 An Open Randomised Trial to Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Monotherapy Induced Gynaecomastia and/or Breast Pain in Prostate Cancer Patients Completed NCT00590213 Phase 4 Casodex 150mg
33 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
34 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
35 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer Completed NCT00199485 Phase 4 Angelica Sinensis
36 A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer Completed NCT01136226 Phase 4 Eligard (TM)
37 A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Completed NCT02475057 Phase 4 Degarelix (LHRH antagonist);LHRH agonist
38 Radical Prostatectomy and Perioperative Fluid Therapy Completed NCT00771966 Phase 4
39 A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase Completed NCT00470834 Phase 4 dutasteride;placebo;bicalutamide
40 A Pilot Study to Assess the Technical Feasibility of Robotic Assisted Laparoscopic Interpositioning of the AVANCETM Nerve Graft for Reconstruction of the Neurovascular Bundle, With a Twenty-four Month Follow-up Term to Assess Efficacy Completed NCT00953277 Phase 4
41 Multicentre, Single Arm, Open Label, Non Controlled Phase IV Clinical Trial to Evaluate Safety of Cabazitaxel (Jevtana) in Combination With Oral Prednisone (or Prednisolone) for the Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen Completed NCT02074137 Phase 4 CABAZITAXEL XRP6258;Prednisone;Prednisolone
42 The Effect of Zoledronic Acid Compared to Placebo on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy Completed NCT00063609 Phase 4 zoledronic acid
43 Effect of Isoflavones on Cognition, Quality of Life and Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Completed NCT00245518 Phase 4 Isoflavone;Placebos
44 Does Androgen Suppression Treatment In Prostate Cancer Reduce Myocardial Blood Flow Reserve? Completed NCT01230905 Phase 4
45 A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients Completed NCT01753297 Phase 4 Triptorelin 11.25 mg
46 Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Efficacy And Safety Of Dutasteride At Improving Lower Urinary Tract Symptoms In Men With Clinically Localized Prostate Cancer Being Treated With Single-Dose Goserelin, Trans-Urethral Incision Of Prostate, And Interval Brachytherapy Completed NCT00805701 Phase 4 avodart;Placebo
47 A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy Completed NCT02405858 Phase 4 Abiraterone Acetate;Prednisolone
48 The Effect Of Risedronate On Bone Turnover And Bone Mass In Older Men Completed NCT00859027 Phase 4 risedronate;Placebo risedronate oral tablet
49 Randomized Crossover Trial to Assess the Tolerability of GnRH Analogue Administration in Patients With Advanced Prostate Cancer Completed NCT01161563 Phase 4 Triptorelin pamoate;Leuprolide acetate
50 Open Randomized Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy Completed NCT02909049 Phase 4 MIDAZOLAM;MEPIVACAÍNE;FENTANILE;KETAMINE

Search NIH Clinical Center for Prostate Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aminoglutethimide
bicalutamide
Chlorotrianisene
Cisplatin
CISPLATIN PWDR
Diethylstilbestrol
Estradiol
Estradiol acetate
estradiol cypionate
ESTRADIOL PWDR
estradiol valerate
Estramustine
Estramustine Phosphate Sodium
Estrogens
Estrogens, Conjugated (USP)
Estrogens, Esterified (USP)
Estrone
Ethinyl Estradiol
Etoposide
etoposide phosphate
Finasteride
Flutamide
fosfestrol
Goserelin Acetate
hydroxyurea
Leuprolide
Leuprolide Acetate
Mitoxantrone
Mitoxantrone Hydrochloride
nilutamide
polyestradiol
polyestradiol phosphate
Sodium estrone sulfate
synthetic conjugated estrogens, A
synthetic conjugated estrogens, B

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Prostate Cancer cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: prostatic neoplasms

Genetic Tests for Prostate Cancer

Genetic tests related to Prostate Cancer:

# Genetic test Affiliating Genes
1 Familial Prostate Cancer 29
2 Malignant Tumor of Prostate 29 AR BRCA2 CDH1 CHEK2 KLF6 MAD1L1 MXI1 PTEN ZFHX3
3 Prostate Neoplasm 29

Anatomical Context for Prostate Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Prostate Cancer:

19
Prostate

MalaCards organs/tissues related to Prostate Cancer:

40
Prostate, Bone, Breast, Testes, Lymph Node, Lung, T Cells

Publications for Prostate Cancer

Articles related to Prostate Cancer:

(show top 50) (show all 42026)
# Title Authors PMID Year
1
KLF6, a candidate tumor suppressor gene mutated in prostate cancer. 54 61 56 6
11752579 2001
2
Mutation of the MXI1 gene in prostate cancer. 54 61 56 6
7773287 1995
3
Multiple newly identified loci associated with prostate cancer susceptibility. 61 56 6
18264097 2008
4
Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP. 54 56 6
16189707 2005
5
-160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. 54 56 6
14961571 2004
6
Multiple loci identified in a genome-wide association study of prostate cancer. 56 6
18264096 2008
7
Induced chromosomal proximity and gene fusions in prostate cancer. 54 61 56
19933109 2009
8
BRCA2 mutation in a family with hereditary prostate cancer. 54 61 6
11170288 2001
9
A candidate prostate cancer susceptibility gene at chromosome 17p. 54 61 6
11175785 2001
10
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. 61 56
29950727 2018
11
Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer. 61 56
24796539 2014
12
Early detection of prostate cancer: AUA Guideline. 61 6
23659877 2013
13
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. 61 56
23727860 2013
14
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. 61 56
23239736 2012
15
The mutational landscape of lethal castration-resistant prostate cancer. 61 56
22722839 2012
16
Germline mutations in HOXB13 and prostate-cancer risk. 61 6
22236224 2012
17
The genomic complexity of primary human prostate cancer. 61 56
21307934 2011
18
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. 61 56
21289624 2011
19
Identification of a cell of origin for human prostate cancer. 61 56
20671189 2010
20
MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. 54 61 46
20332243 2010
21
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. 61 56
20220849 2010
22
Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. 54 6
19383797 2009
23
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. 54 6
19042984 2008
24
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. 54 56
17637754 2008
25
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. 54 56
17671502 2007
26
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. 54 56
17377533 2007
27
A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. 54 6
17085682 2006
28
A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. 54 6
16155194 2006
29
Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. 54 6
16609730 2006
30
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. 54 56
16254181 2005
31
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. 61 56
15988677 2005
32
Global histone modification patterns predict risk of prostate cancer recurrence. 61 56
15988529 2005
33
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. 54 6
15750593 2005
34
CHEK2 is a multiorgan cancer susceptibility gene. 54 6
15492928 2004
35
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. 61 56
14711987 2004
36
No association of germline alteration of MSR1 with prostate cancer risk. 54 6
12958598 2003
37
Genetic counseling for prostate cancer risk. 61 56
12694223 2003
38
Mutations in CHEK2 associated with prostate cancer risk. 61 6
12533788 2003
39
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. 54 6
12474142 2003
40
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. 54 6
12415269 2002
41
Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer. 54 6
12515253 2002
42
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. 54 6
12244320 2002
43
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. 54 6
11799394 2002
44
Association of common missense changes in ELAC2 ( HPC2) with prostate cancer in a Japanese case-control series. 54 6
12522685 2002
45
ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. 61 6
11507049 2001
46
Delineation of prognostic biomarkers in prostate cancer. 61 56
11518967 2001
47
Linkage of prostate cancer susceptibility loci to chromosome 1. 61 56
11379880 2001
48
Prostate cancer: simplicity to complexity. 61 56
11175773 2001
49
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. 54 56
11164181 2001
50
Genetics of prostate cancer: too many loci, too few genes. 61 56
11067781 2000